Is Compounded Semaglutide Legal for Medspas? FDA Status, Compounding Rules, and Enforcement Risk

Semaglutide compounding became widespread during the 2021–2023 shortage of Ozempic and Wegovy, when legitimate supply constraints existed. The FDA's 503A and 503B compounding rules explicitly allow pharmacies to compound drugs when FDA-approved versions are unavailable or in short supply. That shortage has resolved. Novo Nordisk's manufacturing capacity has normalized, and both Ozempic (for diabetes) and Wegovy (for weight loss) are now regularly available through standard pharmaceutical channels.

The FDA issued guidance in 2023 reiterating that compounding semaglutide outside of a documented shortage lacks legal justification. State pharmacy boards have begun enforcing this standard, issuing cease-and-desist letters to compounding pharmacies and revoking licenses in some cases.

503A vs. 503B: The Regulatory Framework

503A pharmacies (traditional compounders) can compound semaglutide for individual patients with a valid prescription from a licensed prescriber, provided they meet USP <797> sterility and potency standards. This is the pathway most medspas use: a patient receives a prescription from a physician or nurse practitioner, and a 503A pharmacy prepares the dose.

503B outsourcing facilities operate under a different regime and can compound drugs without a patient-specific prescription, but they are subject to stricter FDA oversight, including facility inspections and adverse-event reporting. A 503B facility compounding semaglutide without a documented shortage faces heightened regulatory scrutiny.

For a medspas, the distinction is practical: if you source semaglutide from a 503A pharmacy, you depend on that pharmacy's compliance with the shortage justification. If the pharmacy is later found to have compounded without legitimate shortage justification, the liability cascades to your practice.

Enforcement and Liability Risk

The FDA has not yet launched a coordinated enforcement campaign against medspas dispensing compounded semaglutide, but state pharmacy boards and medical boards have. Several states—including California, Florida, and New York—have issued warnings to compounding pharmacies and have begun investigating medspas that advertise semaglutide for weight loss.

The enforcement risk hinges on two factors:

• Prescriber scope: If a medspas physician or nurse practitioner prescribes semaglutide off-label for weight loss (not diabetes), and the compounding pharmacy lacks a shortage justification, both entities are exposed. Some state medical boards view this as practicing outside the standard of care or dispensing an unapproved drug.

• Marketing and intent: Medspas that actively market "compounded semaglutide" as a weight-loss alternative to Wegovy signal intent to circumvent the approved product. This invites board scrutiny.

The Practical Path Forward

Medspas seeking to offer semaglutide for weight loss have a clear legal alternative: source FDA-approved Wegovy through a licensed pharmaceutical wholesaler and dispense it under a valid prescription. This eliminates compounding-related risk entirely.

If a medspas chooses to source compounded semaglutide, verify that the compounding pharmacy can document a current shortage justification with the FDA and your state pharmacy board. Request written confirmation from the pharmacy that it is compounding in compliance with USP <797> and state pharmacy law. Document the prescriber's clinical rationale and ensure it aligns with the standard of care in your state.

Consult your state medical board and pharmacy board directly; compounding law varies by state, and enforcement priorities shift. The safest posture is to treat compounded semaglutide as a transitional option, not a sustainable business model.